Comparative Pharmacology
Head-to-head clinical analysis: PLENDIL versus VERARD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PLENDIL versus VERARD.
PLENDIL vs VERARD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cells, leading to vasodilation and reduced peripheral vascular resistance.
Verard (vericiguat) is a soluble guanylate cyclase (sGC) stimulator. It sensitizes sGC to endogenous nitric oxide (NO) and directly stimulates sGC independently of NO, thereby increasing cyclic guanosine monophosphate (cGMP) production, leading to vasodilation and anti-remodeling effects in the heart and vasculature.
Initial: 5 mg orally once daily. Maintenance: 2.5–10 mg orally once daily. Maximum: 10 mg/day.
400 mg orally twice daily for 14 days
None Documented
None Documented
Terminal elimination half-life 2-5 hours in healthy adults; 7-12 hours in patients with hepatic impairment or advanced age
Terminal elimination half-life 12-15 hours; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min).
Renal (approximately 70% as metabolites, <0.5% unchanged); fecal (approximately 10%)
Renal excretion (70% unchanged, 20% as inactive metabolites), biliary/fecal (10%).
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker